Information Provided By:
Fly News Breaks for April 13, 2015
ARWR
Apr 13, 2015 | 09:55 EDT
Piper Jaffray noted that the FDA lifted its partial hold on ARC-520 after Arrowhead adjusted the protocol for the trial by lowering the first dose and that the company expects to report top-line data single administration results from another ARC-520 trial this quarter. The firm thinks ARC-520 data will be the primary driver for the stock, but sees an opportunity for Arrowhead to be "much more" than just a play on HBV and reiterates its Overweight rating and $12 price target on the stock, which is up 6.5% to $8.44 in early trading.
News For ARWR From the Last 2 Days
There are no results for your query ARWR